Cargando…
Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone that has undergone a revolutionary turnaround from discovery to clinically approved therapeutic. Rapid progress in drug design and formulation has led from initial development of short‐ and long‐acting drugs suitable for daily or weekly parenter...
Autores principales: | Tanday, Neil, Flatt, Peter R., Irwin, Nigel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820187/ https://www.ncbi.nlm.nih.gov/pubmed/33822370 http://dx.doi.org/10.1111/bph.15485 |
Ejemplares similares
-
Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021) -
Glucagon‐like peptide‐1 (GLP‐1) signalling in the brain: From neural circuits and metabolism to therapeutics
por: Kabahizi, Anita, et al.
Publicado: (2021) -
Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021) -
The therapeutic potential of GLP‐1 receptor biased agonism
por: Jones, Ben
Publicado: (2021) -
Reappraising the role of the vagus nerve in GLP‐1‐mediated regulation of eating
por: Brierley, Daniel I., et al.
Publicado: (2021)